The invention relates to a novel synthetic method for tofacitinib intermediate (3R,4R)-N,4-dimethyl-1-benzyl-3-piperidinamine and oxalate hydrates of (3R,4R)-N,4-dimethyl-1-benzyl-3-piperidinamine. The method comprises the following steps: 3-amino-4-methylpyridine is taken as a starting material, amino of 3-amino-4-methylpyridine is subjected to a reaction with ortho-formate, imino formate is generated, and after simple concentration, an N-methyl derivative is obtained by reduction with metal borohydride; after Boc protection, quaternary ammonium salt is generated from a product and benzyl halide and reduced by metal borohydride, a product is subjected to selective hydrogenation with an Rh catalyst, a compound with rich (3R,4R-rel-) configuration is formed, deprotection, salifying and resolution are performed by a hydrochloric acid/alcohol system for removing a (3R,4S-rel-) isomer pair, an obtained (3R,4R-rel-) configuration product is subjected to free treatment and resolved by L-DTTA, and a 3R,4R- configuration product is obtained; after free treatment of salt obtained after resolution, oxalate is formed and purified, a small quantity of remaining 3S,4S-isomers are further removed, and corresponding (3R,4R)-N,4-dimethyl-1-benzyl-3-piperidinamine with high purity and high optical purity is obtained. Through the adoption of the method, safe, simple and industrial large-scale preparation of the tofacitinib intermediate (3R,4R)-N,4-dimethyl-1-benzyl-3-piperidinamine oxalate hydrates is better facilitated.